Click for ALL Botox clinics in the UK & Ireland registered and verified by Consulting Room.
Narrow down your search for your local area.
Currently the number one non-surgical aesthetic treatment in the U.S., Botox® is also the leading brand of botulinum toxin type - A in terms of documented clinical trials and practical use around the world.
It was the first botulinum toxin to gain a cosmetic licence endorsing its use for glabellar lines and wrinkles (as well as also being the first to get a licence for a crow`s feet indication). It is approved for glabellar treatments in the U.S. and around twelve other countries in the world, and was licenced for this use in the U.K. in March 2006 under the brand name Vistabel®.
Most of the literature on Botulinum Toxin, and hence the clinical evidence and statistics, are based on Botox® as this brand represents around 80% of the world’s use of Botulinum Toxin.
Because it is a prescription only medicine; it had to undergo strict clinical trials in the U.S., where it is approved for cosmetic use, in order to gain a license. Remember, the drug has been licensed in the U.S. since the late 1980s.
The graph below shows the results of a study published in 2001.
Data taken from Carruthers, Lowe, & Menter; One year study on the safety and efficacy of Botulinum toxin in Patients with Glabellar Lines; Presented at the AAD March 2001.
On the basis of this evidence, most practitioners would now recommend an initial course of Botox® treatment every 3 or 4 months for the first year. It now appears that after this, the time between future injections may lengthen, with practitioners reporting that some patients may only need to return twice a year to maintain results.